Pharmaceutical Commerce

Featured Content

Pharmaceutical Commerce - August 2025

Click here to read the articles and view the interactive digital edition

Pharma Wholesalers: Looking for Growth

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

340B Litigation and the Path Toward Transparent Drug Discount Programs

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

April 30, 2025

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

Asembia 2025: Rethinking the Drug Distribution Process

April 30, 2025

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

Asembia 2025: Understanding the Inflation Reduction Act

April 30, 2025

A seminar shares key observations and learnings from the first round of direct price negotiations.

Asembia 2025: Rare Disease Therapies Drive Shift in Drug Development Focus

April 30, 2025

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.

Asembia 2025: How AI and Payer Collaboration Are Shaping Pharmacy's Future

April 29, 2025

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase of growth and efficiency in specialty pharmacy.

Asembia 2025: A General Landscape of the Pharmaceutical Industry

April 29, 2025

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Asembia 2025: Navigating the Product Commercialization Process

April 29, 2025

Brett Casper explores the marketplace complexities that manufacturers face regularly.

Asembia 2025: Bridging Health Gaps Through Equity and Education

April 29, 2025

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.

Asembia 2025: The Specialty Pharma Pipeline

April 29, 2025

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

Asembia 2025: The Role of Face-to-Face Connection in Pharma Commercialization

April 28, 2025

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping life sciences companies deliver therapies more efficiently to patients.